Clinical trials: Respiratory Symptoms
COPD
A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD
AER-01-002 is a Phase 2a study being conducted to determine if inhaled fexlamose is an effective and safe treatment for adults with moderate to severe COPD. Study will compare active drug to placebo.
- Trial name
- AER-01-002 (NCT06731959)
- Testing
- Flexlamose
- Volunteers
- 100 people
- Sponsor
- Aer Therapeutics
Alpha 1-Antitrypsin Deficiency
The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency
The objective of this study is to prospectively assess whether there is any interval between first symptom and initial diagnosis that is experienced by patients with newly diagnosed alpha-1 antitrypsin deficiency (AATD) and then…
- Trial name
- NCT03039335
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Biocerna LLC
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the safety and efficacy of inhaled PT001 compared to placebo and tiotropium in patients with mild to moderate chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00871182
- Testing
- Inhaled PT001, Tiotropium Handihaler
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease
The aim of this postmarketing surveillance is to obtain further information about the tolerability and efficacy of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions…
- Trial name
- NCT02231424
- Testing
- Drug: Berodual®
- Volunteers
- 713 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444.
- Trial name
- COPD (NCT01323660)
- Testing
- GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 307 people
- Sponsor
- GlaxoSmithKline
Respiratory Symptoms, Signs and Symptoms, Digestive
Evaluation of the Composition of Human Milk and Health Outcomes in Children
This study is an evaluation of the composition of human milk and health outcomes in children.
- Conditions
- Respiratory Symptoms, Signs and Symptoms, Digestive, Anemia
- Trial name
- NCT01431482
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- Mead Johnson Nutrition
COVID-19
IH Convidecia as Second Booster Dose Against Breakthrough Infections
This will be a randomized single-blind controlled trial to determine the immunogenicity, efficacy and safety of IH Convidecia (CanSino), as a second booster vaccination against Omicron and other emerging VOCs to prevent…
- Trial name
- NCT05517642
- Testing
- Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH), mRNA vaccine BNT162b2 (Pfizer)
- Where
- Malaysia
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Pulmonary Disease, Chronic Obstructive
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
This is a Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of two doses of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder via a Novel Dry…
- Trial name
- NCT01316913
- Testing
- GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719
- Where
- 100 sites in United States, Argentina and 8 more
- Volunteers
- 872 people
- Sponsor
- GlaxoSmithKline
Pulmonary Embolism, Deep Vein Thrombosis
Angel® Catheter Early Feasibility Clinical Study
The primary objective of this clinical trial is to obtain initial insights into the safety of the Angel® Catheter in critically ill subjects with high risk of venous thromboembolism (VTE) disease AND who are not receiving…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Trial name
- NCT01847196
- Testing
- Angel® Catheter
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- BiO2 Medical
Apnea, Respiration
Functional Bed Sheet Capturing Pressure Variation and Respiratory Effort Over Time
Apnea, a cessation in breathing is critical condition that affects the person regardless of age. In infants, an apneic state occurs when there is an absence of respirations for 20 seconds (Alvaro \& Rigatto, 2012).
- Trial name
- NCT03119103
- Testing
- Functional Bed Sheet
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Studio 1 Labs
Advanced Emphysema
A Dose Ranging Study of the Aeris Polymeric Lung Volume Reduction (PLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema
This is a multi-center, open-label, non-controlled Pilot Study. Approximately 24 patients will be assigned to one of 3 treatment groups (8 patients each group).
- Trial name
- NCT00884962
- Testing
- Polymeric Lung Volume Reduction System (PLVR)
- Where
- 6 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Aeris Therapeutics
Sleep Apnea
Mapping for Acute Transvenous Phrenic Nerve Stimulation Study
The Mapping for Transvenous Phrenic Nerve Stimulation Study (MAPS) is being conducted to evaluate the feasibility of transvascular stimulation of phrenic nerves via an electrophysiology (EP) catheter advanced into the great veins.
- Trial name
- MAPs (NCT01981590)
- Testing
- Stimulating the phrenic nerve intravenously using high frequency electrical pulses using an EP catheter connected to external pulse stimulator.
- Where
- 2 sites in Netherlands, Sweden
- Volunteers
- 15 people
- Sponsor
- Medtronic BRC
COPD
A COPD Data Registry for Participants With Frequent Exacerbations
This registry will collect data on COPD, including the course of disease, treatment patterns, and potential new therapies. The registry will also track the experience of participants and caregivers in clinical practice.
- Trial name
- AIREIC (NCT07059273)
- Sponsor
- Hoffmann-La Roche
COPD, Heterogeneous Emphysema
To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr Valves
To compare the clinical outcomes of Endoscopic Lung Volume Reduction (ELVR) using Pulmonx Zephyr Valves vs. Standard of Care (SoC) in the treatment of heterogeneous emphysema subjects in a controlled trial design setting.
- Trial name
- TRANSFORM (NCT02022683)
- Testing
- ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 97 people
- Sponsor
- Pulmonx Corporation
Chronic Bronchitis
RejuvenAir® System Trial for COPD With Chronic Bronchitis
Chronic Obstructive Pulmonary Disease (COPD) is defined as an impaired ability to move air within the lungs and is a major public health problem that is projected to rank fifth worldwide in terms of disease burden and third in…
- Trial name
- SPRAY-CB (NCT03893370)
- Testing
- RejuvenAir System
- Where
- 27 sites in United States, United Kingdom
- Volunteers
- 210 people
- Sponsor
- CSA Medical, Inc.
Chronic Obstructive Pulmonary Disease
Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)
This non-interventional study is to analyse the therapeutic effectiveness in patients with severe COPD following a generally accepted 12-week treatment period with Symbicort Turbuhaler, which could anyhow be shortened or extended…
- Trial name
- NCT00837629
- Volunteers
- 743 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness
The purpose of this study is to show bioequivalence of test product to reference product based on baseline-adjusted forced expiratory volume in one second (FEV1).
- Trial name
- NCT03137992
- Testing
- Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®)
- Where
- 34 sites in United States
- Volunteers
- 377 people
- Sponsor
- Lupin, Inc.
Pulmonary Disease, Chronic Obstructive
Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This exploratory study will compare the efficacy of the fixed-dose combination (FDC) of aclidinium bromide and formoterol fumarate once daily in the morning and placebo once in the evening vs.
- Trial name
- NCT00706914
- Testing
- Once-daily aclidinium/formoterol, Twice-daily formoterol fumarate, Once-daily formoterol fumarate
- Where
- 40 sites in United States
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Obstructive Sleep Apnea, Obesity
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with moderate to severe obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP)…
- Trial name
- SURMOUNT-OSA (NCT05412004)
- Testing
- Tirzepatide
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 469 people
- Sponsor
- Eli Lilly and Company
Pneumonia, Ventilator-Associated
Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients
Randomized, placebo-controlled, partially blinded phase 2 pilot study. Multicenter study (approximately 50 centers) in approximately 9 countries. Proposed start date is December 2008.
- Trial name
- NCT00876252
- Testing
- IC43
- Where
- Austria
- Volunteers
- 400 people
- Sponsor
- Valneva Austria GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.